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Summary
Background: The definitive diagnosis of visceral leishmaniasis (VL) requires invasive procedures
with demonstration of amastigotes in tissue or promastigotes in culture. Unfortunately, these
approaches require laboratory materials not available in poor countries where the disease is
endemic. The correct diagnosis of VL is important, and made more difficult by the fact that
several common tropical diseases such as malaria, disseminated tuberculosis, and enteric fever
share the same clinical presentation. Serological tests have been developed to replace para-
sitological diagnosis in the field. A commercially available K39-based strip test for VL has been
developed for this purpose. The endemic area of leishmaniasis in Brazil overlaps the endemic area
of Chagas disease, a disease that can cause false-positive serological test results. The aim of this
study was to evaluate the incidence of false-positive exams using a rapid test for VL in patients
with Chagas disease.
Methods: A rapid test based on the recombinant K39 antigen of Leishmania was used in: (1) 30
patients with confirmed Chagas disease, (2) 30 patients with a serological diagnosis of Chagas
disease by ELISA, indirect immunofluorescence, indirect hemagglutination, and chemilumines-
cence, (3) 30 healthy patients from a non-endemic area as the control group, (4) 30 patients with
confirmed VL, and (5) 20 patients with proved cutaneous leishmaniasis.
Results: The sensitivity and specificity of the rapid strip test were 100% when compared with
healthy volunteers and those with confirmed Chagas disease. One false-positive result occurred in
the group with Chagas disease diagnosed by serological tests (specificity of 96%).* Corresponding author. Tel.: +55 11 30696530; fax: +55 11 30697508.
1201-9712/$36.00 # 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2008.06.003
Conclusion: The rapid test based on recombinant K39 is a useful diagnostic assay, and a false-
positive result rarely occurs in patients with a serological diagnosis of Chagas disease.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infection with Leishmania spp affects more than 12 million
people worldwide, and approximately 350 million people live
in areas of active parasite transmission.1 Developed coun-
tries continue to remain alert to this protozoan infection due
to the possibility of the disease occurring in tourists returning
from endemic countries where the disease is a public health
problem.2 Leishmaniasis is one of the 13 neglected infectious
diseases with significant morbidity and mortality.3 It is dis-
tributed, in its visceral, mucosal, and cutaneous forms,
through more than 90 countries in Africa, America, Asia,
and Europe.4
The diagnosis of visceral leishmaniasis (VL) can be con-
firmed through demonstration of amastigotes in tissue or
promastigotes in culture. Unfortunately this method requires
invasive procedures and a well-equipped laboratory. The
most sensitive approach is splenic aspiration, an unsafe
procedure if undertaken by inexperienced operators. Some
very common tropical diseases such as malaria, disseminated
tuberculosis, and enteric fever share the same clinical pre-
sentation, hence confirmation of VL is needed for correct
treatment. These diagnostic problems associated with the
disease occurring in poor countries, have urged the devel-
opment and evaluation of cheap and practical tests, with
high sensitivity and specificity for the diagnosis of VL.
Serological tests have been developed to replace para-
sitological diagnosis in the field. A commercially available
K39-based strip test for VL has been developed for this
purpose. This Leishmania antibody-based test is very specific
and comprises a rapid, inexpensive, and noninvasive field-
suitable test that requires one drop of whole blood or serum.
In India, this test was found to be sensitive (99—100%) and
specific (95—100%) for the noninvasive diagnosis of visceral
leishmaniasis.5
Leishmania chagasi is the species that historically causes
VL in Brazil and in other Latin American countries. The
endemic area of leishmaniasis in Brazil overlaps the endemic
area of Chagas disease. This curious coincidence may be a
cause of false-positive results of some serological tests due to
cross-reacting antibodies when these parasites are under
clinical investigation.6
Therefore, we conducted a study in patients with Chagas
disease to determine the frequency of false-positive exams
with this rapid strip test.
Materials and methods
Serum samples
This study was conducted at the Laboratory of Medical
Investigation in Parasitology (LIM 46) and Immunology (LIM
48), Hospital das Clı´nicas, University of Sao Paulo, Brazil.
Sera from 140 untreated patients were tested: (1) 30
patients with confirmed Chagas disease by blood culture withtrypomastigotes as previously described,7,8 (2) 30 patients
with a negative blood culture, but with a serological diag-
nosis of Chagas disease using four methods, where all were
positive (ELISA, indirect immunofluorescence, indirect
hemagglutination, and chemiluminescence) as previously
described,9 (3) 30 healthy patients from a non-endemic area
as the control group, (4) 30 patients with confirmed VL by
demonstration of amastigotes in tissue, and (5) 20 patients
with proved cutaneous leishmaniasis by identification of
amastigotes on skin biopsy or positive immunohistochemistry
as previously described.10
Rapid test
The test we used (DiaMed-IT LEISH1, DiaMed AG, Cressier sur
Morat, Switzerland) includes a test strip, a conjugate and
wash well, one dropper ampoule with buffer and one pipette,
a lancet, and a disinfecting swab. The dipstick presents two
bands, a control band and a band with recombinant K39
antigen of Leishmania spp. One drop of buffer was added
to the first well with conjugate and four drops were added to
the wash well. Each patient was tested separately with one
kit, adding 10 ml of serum to the first well (conjugate). After
1 min, the strip was placed upright for 10 min in the con-
jugate well until the buffer—serum solution had been
absorbed. The result was positive if the control band was
clearly visible and the second band — a red/purple line —
indicated the presence of anti-K39 antibody as previously
described.5
Statistical analysis
Data were initially entered in an Excel data sheet and later
analyzed with SPSS 11.0 for Windows (SPSS, Inc., Chicago, IL,
USA). Sensitivity, specificity, and positive and negative pre-
dictive values, with 95% confidence intervals (95% CI), were
calculated and compared for the groups of VL and non-VL
patients, including direct comparison with the group with
Chagas disease.
Results
The sensitivity and specificity of the rapid strip test in the
diagnosis of VL were 100% when compared with healthy
volunteers and those with confirmed Chagas disease by blood
culture. When the diagnosis of Chagas disease was deter-
mined by serological exams, there was one false-positive
case from the 30 patients tested (Tables 1 and 2). The
positive predictive value and specificity of the rapid test
in the diagnosis of VL decreased from 100% to 97% and 96%,
respectively. We also tested the rapid dipstick exam in
patients with cutaneous leishmaniasis. This evaluation
showed the cross-reaction between the diseases, although
the specificity and positive predictive value persisted with
high values, 80% and 88%, respectively.
Table 2 Sensitivity, specificity, PPV, and NPV of a rapid K39-based strip test for the detection of leishmaniasis in patients with
confirmed Chagas disease and Chagas disease by serodiagnosis
Control groupa Visceral leishmaniasis
Sensitivity Specificity PPV NPV
% CI % CI % CI % CI
Healthy volunteers 100 (85—100) 100 (85—100) 100 (85—100) 100 (85—100)
Chagas disease (blood culture) 100 (85—100) 100 (85—100) 100 (85—100) 100 (85—100)
Chagas disease (serology) 100 (85—100) 96 (81—99) 97 (81—99) 100 (85—100)
Cutaneous leishmaniasis 100 (85—100) 80 (56—93) 88 (72—96) 100 (76—100)
PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval.
a Control group vs. visceral leishmaniasis.
Table 1 Rapid K39-based strip test results in patients with confirmed Chagas disease and Chagas disease by serodiagnosis
Visceral
leishmaniasis
Healthy
volunteers
Chagas disease
(blood culture)
Chagas disease
(serology)a
Cutaneous
leishmaniasis
Total
Rapid test positive 30 0 0 1 4 35
Rapid test negative 0 30 30 29 16 105
Total 30 30 30 30 20 140
a Serology tests were ELISA, indirect immunofluorescence, indirect hemagglutination, and chemiluminescence. A TESA blot was also
performed in the false-positive case.
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This study shows that cross-reaction between Chagas dis-
ease and VL using the rapid strip test with K39 recombinant
antigen is very rare. We demonstrated the absence of
cross-reaction in 30 patients with Chagas disease diag-
nosed with a gold standard method (blood culture). Never-
theless, one patient from 30 patients with a serological
diagnosis of Chagas disease showed a positive test to VL.
Four methods (ELISA, indirect immunofluorescence, indir-
ect hemagglutination, and chemiluminescence) were used,
and the patients with a serological diagnosis of Chagas
disease were positive by all these exams. Hence, we
performed another serum test in the patient with a
false-positive, with higher sensitivity and specificity, the
TESA blot (trypomastigote excreted—secreted antigens),
and the result of this test was also positive.11,12 A possible
explanation for this false-positive result could be a pre-
vious, recently cured, or asymptomatic VL with persistence
of antibodies against the antigen K39. This patient was
tested for other antigens of Leishmania, as well as with
other serological methods, but the results were negative.
The serum from this patient was tested by immunoblot of
L. chagasi, which has a reactivity >85% with a specificity of
94% and a sensitivity of 89.8% (personal communication). A
Montenegro skin test was not performed because the
positivity of this test in patients from endemic areas is
extremely high.
The ELISA test used, available in the form of several
commercial kits, employs antigens obtained by the lysis of
trypomastigote forms of Trypanosoma cruzi. This test is
sensitive, however it fails to distinguish T. cruzi antibodies
from Leishmania spp antibodies, thus frequently leading to
false-positive results.13,14 The other tests we used, indirectimmunofluorescence, indirect hemagglutination, and chemi-
luminescence, share high sensitivity but also fail to distin-
guish T. cruzi and Leishmania spp antibodies. This can occur
with some TESA-based assays too.15
K39 is a gene sequence that encodes a conserved pro-
tein between L. chagasi and Leishmania donovani. This
gene is part of a kinesin-related protein expressed by
amastigotes. More than 98% of Brazilian patients with VL
were found to present high levels of the protein coded by
K39.16
Several antigens have been tested for the development
of serological assays for the diagnosis of VL. Some of them
have shown high specificity and others not so much. The
low specificity of some assays is directly related to
increased numbers of false-positive results. Leishmania
and Trypanosoma are genera from the same family. Despite
some theories about clonality/sexuality and the concept
of species/genus, these genera share some antigen
genes. This can cause false-positive results of serological
tests due to cross-reacting antibodies when either of
these parasites is under clinical investigation.6 Hence,
there is mounting interest in the development of a ser-
ological test having the higher specificity but giving a low
number of false-positive results. Although we found one
false-positive case, we may consider the pre-test prob-
ability of each disease, and not consider a positive-test in a
patient with a low pre-test probability (screening of blood
bank). Patients with cutaneous leishmaniasis may also test
positive.
The rapid test based on recombinant K39 is a useful
diagnostic assay, although false-positive results can occur
in patients with a serological diagnosis of Chagas disease and
in patients with cutaneous leishmaniasis in rare circum-
stances.
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